Q4 2019 13F Holders as of 31 Dec 2019
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
62.2M
-
Number of holders
-
79
-
Total 13F shares, excl. options
-
23.2M
-
Shares change
-
+1.73M
-
Total reported value, excl. options
-
$164M
-
Value change
-
+$7.87M
-
Number of buys
-
49
-
Number of sells
-
-26
-
Price
-
$7.05
Significant Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) as of Q4 2019
90 filings reported holding PTGX - Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 as of Q4 2019.
Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) has 79 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 23.2M shares
of 62.2M outstanding shares and own 37.31% of the company stock.
Largest 10 shareholders include FMR LLC (4.08M shares), RTW INVESTMENTS, LP (2.46M shares), Johnson & Johnson Innovation - JJDC, Inc. (2.45M shares), BlackRock Inc. (1.56M shares), FARALLON CAPITAL MANAGEMENT LLC (1.5M shares), BAKER BROS. ADVISORS LP (1.17M shares), VANGUARD GROUP INC (990K shares), MILLENNIUM MANAGEMENT LLC (847K shares), BVF INC/IL (683K shares), and DIMENSIONAL FUND ADVISORS LP (671K shares).
This table shows the top 79 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.